This HTML5 document contains 110 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
wdt	http://www.wikidata.org/prop/direct/
wdtn	http://www.wikidata.org/prop/direct-normalized/
schema	http://schema.org/
rdfs	http://www.w3.org/2000/01/rdf-schema#
skos	http://www.w3.org/2004/02/skos/core#
wikibase	http://wikiba.se/ontology#
p	http://www.wikidata.org/prop/
n11	http://dx.doi.org/10.1200/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n12	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdh	http://www.w3.org/2001/XMLSchema#
wds	http://www.wikidata.org/entity/statement/
wd	http://www.wikidata.org/entity/

Statements

Subject Item

wd:Q37496425

rdf:type

wikibase:Item

schema:description

2009年學術文章 artículu científicu espublizáu en 2009 επιστημονικό άρθρο wissenschaftlicher Artikel 2009年学术文章 mokslinis straipsnis مقالهٔ علمی სამეცნიერო სტატია 2009年學術文章 vědecký článek scienca artikolo artikulong pang-agham articol științific мақолаи илмӣ 2009年の論文 vitenskapelig artikkel vedecký článok naučni članak научная статья 2009年学术文章 מאמר מדעי artigo científico (publicado na 2009) tudományos cikk bài báo khoa học 2009年学术文章 article scientific artigo científico (publicado na 2009) บทความทางวิทยาศาสตร์ 2009年学术文章 2009年學術文章 научни чланак tieteellinen artikkeli مقالة علمية نشرت في 26 مايو 2009 artykuł naukowy artículo científico publicado en 2009 vitskapeleg artikkel artikull shkencor wetenschappelijk artikel article científic ২০০৯-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ мақолаи илмӣ 2009年學術文章 teaduslik artikkel научна статия 2009年学术文章 vetenskaplig artikel 2009년 논문 articolo scientifico artigo científico سائنسی مضمون наукова стаття, опублікована в травні 2009 գիտական հոդված scientific article published on 26 May 2009 2009年學術文章 article scientifique publié en 2009 2009年學術文章 научни чланак 2009 nî lūn-bûn bilimsel makale videnskabelig artikel (udgivet 2009)

p:P577

wds:Q37496425-84158F1C-7F99-4EBD-9DED-2BEA88FF4AE1

wdt:P577

2009-05-26T00:00:00Z

p:P407

wds:Q37496425-68CE2930-1F96-4088-A28B-80C89F84064A

wdt:P407

wd:Q1860

p:P2093

wds:Q37496425-714DEE48-8CAF-4876-A79A-A2ABDDCDE062 wds:Q37496425-7AAE070F-2C02-4C8B-A637-AB0C1C32AC0B wds:Q37496425-C0D0928A-F3FC-4974-9B6F-DFF14C042CC3 wds:Q37496425-98C0BD2A-EC42-4870-8F90-5698B0FF2720 wds:Q37496425-5C0CD575-DBA2-44DB-96CD-9040B71F8E9A wds:Q37496425-5398E095-A33E-4266-A84C-07BEA0409C96 wds:Q37496425-E42AB6A5-72D9-4868-9C5B-D28041D520AF

wdt:P2093

Sergey Cheporov Paul Bhar Anatoly N Makhson William J Gradishar Dimitry Krasnojon Georgiy M Manikhas Alicia Clawson

rdfs:label

Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer

skos:prefLabel

Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer

schema:name

Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer

p:P1476

wds:Q37496425-894A92A4-9EB8-4917-91B1-AA8EB02A7BF7

wdt:P1476

Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer

p:P304

wds:Q37496425-02E259DD-2ED7-403E-8B35-2904E6A30445

wdt:P304

3611-3619

p:P31

wds:Q37496425-1EB824A0-3798-46E9-90A7-228E169E6EFC

wdt:P31

wd:Q13442814

p:P921

wds:Q37496425-3E898386-69E4-4DE1-A43C-4A9522625569 wds:Q37496425-96DF73E5-E243-4499-ACFF-FC5D423C8D29

wdt:P921

wd:Q420436 wd:Q12859063

p:P698

wds:Q37496425-02326B86-25D0-41FE-9235-0F243C5C726B

wdtn:P698

n12:19470941

wdt:P698

19470941

p:P1433

wds:Q37496425-3D7395AC-3F34-4FC1-8D81-91D4AA7E7924

wdt:P1433

wd:Q400292

p:P433

wds:Q37496425-FE78DDA9-AB39-4DAA-A9A1-AA8F2B707B09

p:P478

wds:Q37496425-562EFB03-874A-4ED3-BF1A-3A329AF2C658

wdt:P433

22

wdt:P478

27

p:P356

wds:Q37496425-C8266981-10D2-4264-9B92-3EBD656B5D13

wdtn:P356

n11:JCO.2008.18.5397

wdt:P356

10.1200/JCO.2008.18.5397